Mexico clears Biocon's 'biocomparable' insulin glargine
This article was originally published in Scrip
Mexico has approved Biocon's insulin glargine, the first such product cleared under the Latin American nation's biocomparable approvals pathway defined in 2012. Biocon said that its insulin glargine (Galactus) has been approved by Mexico's Cofepris, through the Indian firm's partner PiSA Farmaceutica. While details on Galactus' pricing were not immediately available, the partners hope to facilitate a lowering of per capita expenditure on diabetes with the use of their "cost effective" insulin glargine. Mexico is estimated to have more than nine million cases of diabetes, with per capita expenditure on the disease as high as $892.5. The market for insulin glargine in Mexico is said to be in excess of $40m, with the overall insulins market estimated at around $150m. The total annual cost of managing diabetes and its complications in Mexico in 2000 was estimated at more than $15bn, of which around $765m represented direct medication costs, data published in the 2003 bulletin of the WHO said.
You may also be interested in...
Aurobindo and Sandoz mutually terminate their planned $1bn deal, leaving many questions on how both sides will re-orient strategies going forward.
Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.
The coronavirus pandemic has thrown up unprecedented challenges for the Indian clinical trials segment, as in other parts of the world. Experts tell Scrip how things are poised in the country including potential impact on some critical milestones, but efforts are underway to tackle the crisis.